ABOS
NASDAQ
US
Acumen Pharmaceuticals, Inc. - Common Stock
$2,70
▲ +$0,15
(+5,88%)
Vol 636K
3
Skor Kualitas
fail
Pendapatan ✗
Laba Bersih ✗
>IPO ✗
Kap. Pasar
$127.8M
ROE
-97,4%
Margin
-509,7%
D/E
32,90
Beta
0,24
52W
$1–$2
Konsensus Wall Street
12 analis · Apr 20266
Beli Kuat
5
Beli
1
Tahan
0
Jual
0
Jual Kuat
91,7%
Peringkat Beli
Grafik Harga
Saham Serupa
PRLD
Prelude Therapeutics Inc
$164.2M
ARTV
Artiva Biotherapeutics Inc
$105.3M
RNAC
Cartesian Therapeutics Inc
$187.5M
WHWK
Whitehawk Therapeutics Inc
$114.1M
NKTX
Nkarta Inc
$131.4M
VTVT
vTv Therapeutics Inc
$167.1M
KALA
KALA BIO Inc
$12.2M
IMUX
Immunic Inc
$64.2M
TNYA
Tenaya Therapeutics Inc
$154.0M
HRTX
Heron Therapeutics Inc
$238.4M
Pendapatan
Tingkat beat: 60,0%
Laporan Berikutnya
Mei 11, 2026
Estimasi EPS: $-0,40
| Kuartal | EPS Estimasi | EPS Aktual | Kejutan |
|---|---|---|---|
| Mar 2026 | $-0,40 | — | — |
| Des 2025 | $-0,46 | $-0,41 | +$0,05 |
| Sep 2025 | $-0,62 | $-0,44 | +$0,18 |
| Jun 2025 | $-0,55 | $-0,68 | $-0,13 |
Pendapatan & Laba Kuartalan
| Kuartal | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Pendapatan | — | — | — | — | — |
| Laba Bersih | -$29.8M | -$37.2M | -$28.8M | -$41.0M | -$26.5M |
Tren Fundamental
| Metrik | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -81.4% | -81.4% | -81.4% | -81.4% | -97.4% | -97.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -509.7% | -509.7% | -509.7% | -509.7% | -509.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 25.52 | 25.52 | 25.52 | 25.52 | 32.90 | 32.90 |
| Current Ratio | 5.97 | 5.97 | 5.97 | 5.97 | 6.02 | 6.02 |
Rasio Utama
ROA (TTM)
-70,4%
P/S (TTM)
88,76
P/B
0,6
EPS (TTM)
$-2,21
CF/Share
$-1,10
52W High
$2,46
52W Low
$0,86
$0,86
Rentang 52 Minggu
$2,46
Kesehatan Keuangan
Arus Kas Bebas
-$30.5M
Utang Bersih
-$16.0M
Kas
$46.8M
Total Utang
$30.8M
Per tanggal Sep 30, 2025
Як ABOS виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка ABOS vs аналоги Biotechnology
P/E
—
▼
0%
di bawah
rekan
(18,8)
vs Rekan
vs Industri
Undervalued
P/S
88,8
▲
591%
di atas
rekan
(12,9)
vs Rekan
vs Industri
Lebih mahal
P/B
0,6
▼
77%
di bawah
rekan
(2,5)
vs Rekan
vs Industri
Undervalued
Дивідендна дохідність
—
▼
0%
di bawah
rekan
(0,0%)
vs Rekan
vs Industri
Yield rendah
Прибутковість ABOS vs аналоги Biotechnology
ROE
-97,4%
▼
45%
di bawah
rekan
(-67,3%)
vs Rekan
vs Industri
Lemah
Net margin
-509,7%
▼
78%
di bawah
rekan
(-286,8%)
vs Rekan
vs Industri
Lemah
Валова маржа
—
▼
0%
di bawah
rekan
(78,6%)
vs Rekan
vs Industri
Sejajar
ROA
-70,4%
▼
51%
di bawah
rekan
(-46,7%)
vs Rekan
vs Industri
Lemah
Фінансове здоровʼя ABOS vs аналоги Biotechnology
D/E ratio
32,9
▼
0%
di bawah
rekan
(0,0)
vs Rekan
vs Industri
Utang tinggi
Поточна ліквідність
6,0
▲
36%
di atas
rekan
(4,4)
vs Rekan
vs Industri
Di bawah rata-rata
Beta
0,2
▼
75%
di bawah
rekan
(1,0)
vs Rekan
vs Industri
Lebih volatil
Радар фундаменталів ABOS
ABOS
Median rekan
Industri
ABOS прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ABOS vs аналоги: ключові метрики
Aktivitas Orang Dalam
NeutralPembelian
0
Penjualan
0
RA CAPITAL MANAGEMENT, L.P.
Beneficial Owner of more than… · Mar 16
6060606 shs
MEISNER DEREK M
Officer · Mar 06
2090 shs
MEISNER DEREK M
Officer · Mar 06
2090 shs
MEISNER DEREK M
Officer · Feb 27
9406 shs
MEISNER DEREK M
Officer · Feb 27
9406 shs
MEISNER DEREK M
Officer · Jan 28
17756 shs
MEISNER DEREK M
Officer · Jan 28
17756 shs
MEISNER DEREK M
Officer · Jan 23
8934 shs
WILLIAM MATTHEW ZUGA
Chief Financial Officer · Jan 22
4160 shs
O'CONNELL DANIEL JOSEPH
Chief Executive Officer · Jan 22
12035 shs
Terakhir 90 hari
Pemegang Terbesar
Top 5: 40,18%RA Capital Management, L.P.
24,65%
$33.7M
Sands Capital Alternatives,…
5,64%
$7.7M
Franklin Resources, Inc.
3,81%
$5.2M
FMR, LLC
3,35%
$4.6M
Vanguard Group Inc
2,73%
$3.7M
Per tanggal Des 31, 2025
Berita Terbaru
Belum ada berita terkait